4-HO-MiPT Pellets – 20mg
€ 24,75 – € 250,00Price range: € 24,75 through € 250,00
4-HO-MiPT Pellets are described as compressed research units associated with 4-hydroxy-N-methyl-N-isopropyltryptamine, a compound belonging to the substituted tryptamine family.
The named compound is classified as a 4-hydroxytryptamine derivative and contains an indole framework with a hydroxy substituent and an aminoalkyl side chain.
The supplied source identifies a labeled ingredient quantity per pellet and presents the material for controlled analytical and laboratory research.
Its stated research context includes chemical identification, compound characterization, and reference-oriented laboratory investigation.
However, the precise chemical form, ingredient purity, excipient composition, finished-unit content, and content uniformity have not been independently established.
The source refers to batch tracking, Certificates of Analysis, and laboratory verification where applicable. No actual supporting documentation accompanied these statements.
The finished pellets are not established as certified reference materials or validated quantitative calibration standards.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
4-HO-MiPT Pellets 20mg – Hydroxytryptamine Research Material
Product Overview
4-HO-MiPT Pellets are described in the supplied information as compressed research units associated with 4-hydroxy-N-methyl-N-isopropyltryptamine.
The named compound belongs to the substituted tryptamine family and is classified as a 4-hydroxytryptamine derivative.
Its proposed molecular framework contains a hydroxy-substituted indole ring and an aminoalkyl side chain bearing methyl and isopropyl substituents.
The supplied source presents the material as a laboratory research preparation intended for analytical identification and scientific documentation.
The product description identifies a specific labeled ingredient quantity per pellet.
However, no actual finished-unit assay or content-uniformity report accompanied the information.
The labeled ingredient amount therefore remains a source-provided specification rather than an independently verified analytical result.
The source emphasizes batch documentation, controlled handling, and Research Use Only designation.
These statements identify the intended positioning of the listing but do not independently verify chemical identity, purity, or regulatory compliance.
The finished preparation is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product.
Chemical Identity & Classification
The supplied source identifies 4-HO-MiPT as 4-hydroxy-N-methyl-N-isopropyltryptamine, a substituted tryptamine.
Its chemical classification places it within the 4-hydroxytryptamine subclass of indolealkylamines.
The supplied product information includes:
- Common designation: 4-HO-MiPT
- Chemical name: 4-Hydroxy-N-methyl-N-isopropyltryptamine
- Chemical classification: Substituted tryptamine; 4-hydroxytryptamine derivative
- Reported presentation: Compressed pellets
- Labeled ingredient amount: Specified per finished pellet
- Intended designation: Research Use Only
The source does not provide a CAS Registry Number, molecular formula, molecular weight, systematic chemical name, or confirmed salt form.
These details should not be inferred from the product title alone.
The exact chemical form of the ingredient is relevant to interpreting molecular-weight calculations and quantitative content claims.
The source does not establish whether the finished pellets contain the free base or a specific salt.
No verified structural analysis or batch-specific identity report was supplied.
Researchers may consult PubChem for public chemical-reference information, while ensuring that any selected record corresponds to the actual chemical form being examined.
Chemical & Physical Characteristics
The supplied source describes the product as compressed pellets.
No actual product-specific inspection report, pellet-dimension specification, total unit mass, or excipient list was provided.
The physical presentation therefore remains a source-provided description.
The named compound contains a hydroxy substituent at the 4-position of the indole framework.
Its side-chain nitrogen is described as bearing methyl and isopropyl substituents.
These structural features distinguish 4-HO-MiPT from other substituted tryptamines with different ring or nitrogen substitution patterns.
However, structural classification alone does not establish the physicochemical characteristics of the finished formulation.
The source does not provide experimentally verified melting-point data, solubility measurements, degradation profiles, or complete physical characterization.
The exact salt form, if any, is not identified.
The source also does not specify the additional ingredients that may be present in the compressed preparation.
Consequently, the chemical properties of the named ingredient should not be assumed to describe the entire finished pellet.
The source recommends cool, dry, dark storage while keeping the original packaging intact.
No validated product-specific stability study or established shelf-life specification accompanied that recommendation.
Purity & Analytical Verification
The supplied source states that batch-specific purity information may be available through a Certificate of Analysis.
However, it does not provide a numerical purity specification or an actual analytical report.
No batch-specific chromatogram, mass spectrum, NMR spectrum, or independent laboratory certificate accompanied the information.
Accordingly, no particular purity threshold can be presented as independently verified.
For a compressed preparation, the purity of the named ingredient and its actual quantity within a finished pellet are separate analytical characteristics.
An ingredient-purity result does not independently establish finished-unit content or content uniformity.
The source identifies analytical and reference-oriented research as the intended laboratory context.
However, it does not establish that the finished pellets meet the requirements of a certified reference material.
No assigned measurement values, uncertainty statements, metrological traceability records, or independently verified finished-unit specifications were supplied.
Any product-specific analytical claims should be supported by actual batch documentation.
Quality Control & Batch Integrity
The supplied source refers to Certificates of Analysis, lot tracking, and laboratory verification where applicable.
These statements describe proposed or claimed quality-assurance practices.
No actual certificate, independent testing report, manufacturing audit, laboratory accreditation record, or batch-specific quality-control document accompanied the information.
They therefore remain unverified supplier statements.
For reproducible laboratory documentation, relevant records may include verified chemical identifiers, batch number, analytical findings, receipt date, and available storage history.
For compressed preparations, the identity and purity of the named active compound should be distinguished from the composition and consistency of the finished units.
The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of the labeled ingredient amount.
The existence of a Research Use Only designation does not itself demonstrate manufacturing quality or analytical traceability.
Claims of consistent purity, identity, and formulation quality should be supported by actual records rather than inferred from general quality-assurance language.
Safety, Handling & Laboratory Precautions
4-HO-MiPT is a synthetic substituted tryptamine associated with potentially significant toxicological hazards.
The supplied source does not provide a complete product-specific toxicological assessment.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The compressed presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual finished-unit composition, purity, and chemical form have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes protective packaging, controlled handling, and professional shipment arrangements.
No actual packaging specification, container-validation report, or shipment-condition record was provided.
The source recommends sealed storage in a cool, dry, dark environment and keeping the original blister or container packaging intact.
No validated product-specific stability data was provided to establish a particular storage temperature or shelf life.
Laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
The labeled ingredient quantity should be recorded as a source-provided specification unless independently verified.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.
Intended Research Use & Market Positioning
The supplied scientific context places 4-HO-MiPT within analytical research involving substituted tryptamines, hydroxytryptamine derivatives, and chemical identification.
The source describes the material as intended for controlled laboratory settings and reference-oriented scientific workflows.
These statements identify a research context but do not establish certified reference-material status or validated performance for the actual pellets.
The supplied Raw Lab Chems catalog includes 4-HO-MiPT Pellets, corresponding to the listing discussed here.
For comparative chemical-catalog context, Raw Lab Chems also lists 4-HO-MET Pellets and Metocin 4-HO-MET Blister.
Both related listings refer to 4-HO-MET rather than 4-HO-MiPT.
Although the names indicate membership in a related substituted tryptamine family, the compounds are chemically distinct and should not be treated as analytically interchangeable.
The supplied information does not establish equivalent chemical forms, ingredient purity, or analytical characteristics across these listings.
These references provide catalog context rather than evidence of product equivalence or certified reference-material status.
Ordering, Availability & Fulfillment
The supplied source describes protective packaging and international shipping arrangements.
No current inventory record, shipment authorization, carrier documentation, or verified delivery information was supplied.
Consequently, no availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted.
4-HO-MiPT and related substituted tryptamines may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
4-HO-MiPT is a synthetic substituted tryptamine whose possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction.
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining the applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.